OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Patel on Post-ASCT Complications in Myelofibrosis

February 14th 2023

Sagar Patel, MD, discusses complications following allogeneic stem cell transplant that can occur in patients with myelofibrosis.

Dr. Phillips on the Early Implications of Glofitamab Monotherapy in R/R MCL

February 13th 2023

Tycel Phillips, MD, MPH, discusses the key implications of investigating glofitamab monotherapy in patients with relapsed/refractory mantle cell lymphoma.

Dr. Singh on the Continued Investigation of Enfortumab Vedotin/Pembrolizumab in Urothelial Cancer

February 13th 2023

Vikas Kumar Singh, MD, discusses the potential benefit of the combination of enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.

Dr. Fecteau on the Benefit of a Multidisciplinary Approach in Bladder and Prostate Cancers

February 13th 2023

Ryan Fecteau, MD, PhD, discusses the benefit of utilizing a multidisciplinary approach in bladder and prostate cancers.

Dr. Kim on the Synergistic Effect of PD-1H Blockade in AML

February 13th 2023

Tae Kon Kim, MD, PhD, discusses key results on the synergistic effects of PD-1H blockade in acute myeloid leukemia..

Dr. Goy on Durable Responses With Brexu-cel in the ZUMA-2 Trial in MCL

February 13th 2023

Andre H. Goy, MD, discusses key findings from an assessment of durable responses in the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.

Dr. Haffner Outlines the Unique Genomics of Basal Cell Carcinoma

February 13th 2023

Michael C. Haffner, MD, PhD, explains the genomic differences between prostate adenocarcinoma of the prostate and prostatic basal cell carcinoma, an extremely rare disease.

Dr. Blum on Potential of CA-125 as a Biomarker for Renal Medullary Carcinoma

February 13th 2023

Kyle A. Blum, MD, MS, says that results from a study of patients renal medullary carcinoma suggest that with CA-125, an established biomarker for ovarian cancer, may play a similar role in this rare disease.

Dr. Blum Discusses Survival Outcomes for Patients With Renal Medullary Carcinoma

February 13th 2023

Kyle A. Blum, MD, MS, says that patients with renal medullary carcinoma have poor prognosis, but anecdotal evidence suggests that survival outcomes may be improving.

Dr. Blum Discusses the Challenges of Diagnosing Renal Medullary Carcinoma

February 13th 2023

Kyle A. Blum, MD, MS, discusses how few physicians have experience with renal medullary carcinoma, and the disease often presents with nonspecific symptoms.

Dr. Blum Details Upcoming Research in Renal Medullary Carcinoma

February 13th 2023

Kyle A. Blum, MD, MS, explains how renal medullary cancer, like most rare cancers, can be difficult to study. However, there are several ongoing studies that include this patient population.

Dr. Sahin on the Background of the IMbrave 151 Trial in Biliary Tract Cancer

February 11th 2023

Ilyas Sahin, MD, discusses the background and findings of the phase 2 IMbrave 151 trial in advanced biliary tract cancer.

Dr. Walden on the RNA Expression of Homologous Recombination Genes in CRC

February 10th 2023

Daniel Walden, MD, discusses the association of low expression of RNA of wild-type homologous recombination genes and survival in colorectal cancer.

Dr. Friedland on a Multimodal Screening Blood Test to Detect CRC

February 10th 2023

Shai Friedland, MD, discusses a multimodal screening blood test for advanced adenomas in colorectal cancer.

Dr. Mehta on Frontline and Adjuvant Treatments in ESCC

February 10th 2023

Rutika Mehta, MD, MPH, discusses which patients with esophageal squamous cell carcinoma may benefit most from the different frontline treatment options available and highlights key treatment developments with adjuvant immunotherapy plus chemotherapy.

Dr. Rogers on the Potential for ctDNA to Aid Second-line Treatment Decisions in mCRC

February 10th 2023

Sherise Rogers, MD, MPH, discusses the potential of utilizing circulating tumor DNA to help guide second-line treatment decisions in patients with metastatic colorectal cancer.

Dr. Montero on the FDA Approval of Elacestrant in ER+/HER2– Breast Cancer

February 10th 2023

Alberto Montero, MD, MBA, CPHQ, discusses the significance of the FDA approval of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Dr. Wander on the Role of NF1 Mutations on CDK4/6 Resistance in Breast Cancer

February 10th 2023

Seth Wander, MD, PhD, discusses the investigation of resistance to CDK4/6 inhibitors and the role of NF1 mutations in breast cancer.

Dr. Neven on the Relationship of Cell Cycle Genes and Outcomes in HR+/HER2– Breast Cancer

February 10th 2023

Patrick Neven, MD, discusses the association between cell cycle–related genes and outcomes for patients with hormone receptor–positive/HER2-negative advanced breast cancer treated on the phase 3 MONALEESA-2, MONALEESA-3, and MONALEESA-7 trials.

Dr. Linhares on Patient-Reported Outcomes From the OUTREACH Trial in R/R LBCL

February 10th 2023

Yuliya Linhares, MD, discusses the trial design, methodology, and key efficacy and safety results from the phase 2 OUTREACH trial (NCT03744676) evaluating lisocabtagene maraleucel (liso-cel; Breyanzi) in relapsed/refractory large B-Cell lymphoma (LBCL).